We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Muscle Pharm Corporation (CE) | USOTC:MSLP | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0002 | 0.00 | 01:00:00 |
Nevada
|
000-53166
|
77-0664193
|
(State or other jurisdiction
of incorporation)
|
(Commission File No.)
|
(I.R.S. Employer
Identification Number)
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
·
|
Stated Value
: The stated value per share of the Series C Convertible Preferred Stock is $1000.00.
|
|
·
|
Voting Rights
: The holders of the Series C Convertible Preferred Stock are not entitled to vote with the Company’s common stockholders.
|
|
·
|
Protective Provisions
: As long as any Series C Convertible Preferred Stock is outstanding, we are prohibited from taking any of the following actions without the consent of a majority of the then outstanding Series C Convertible Preferred Stock.
|
|
o
|
(i) alter or change adversely the powers, preferences or rights given to the Series C Convertible Preferred Stock;
|
|
o
|
(ii) alter or amend the certificate of designation;
|
|
o
|
(iii) authorize or create any class of stock ranking as to dividends or distribution of assets upon a liquidation or otherwise senior to or pari passu with the Series C Convertible Preferred Stock;
|
|
o
|
(iv) amend its certificate of incorporation, bylaws or other charter documents so as to affect adversely any rights of any holders of the Series C Convertible Preferred Stock;
|
|
o
|
(v) increase the authorized or designated number of shares of Series C Convertible Preferred Stock;
|
|
o
|
(vi) issue any additional shares of Series C Convertible Preferred Stock; or
|
|
o
|
(vii) enter into any agreement with respect to the foregoing.
|
|
·
|
Voluntary Conversion
: A holder of Series C Convertible Preferred Stock can elect to convert its Series C Convertible Preferred Stock into shares of our common stock at any time from and after the Original Issue Date (as defined in the certificate of designation). Each share of Series C Convertible Preferred Stock is convertible into that number of shares of our common stock determined by dividing the stated value of such share of Series C Convertible Preferred Stock (as increased for accrued dividends) by the conversion price.
|
|
·
|
Conversion Price
: The conversion price is the higher of (i) $0.01 and (ii) such price that is a 50% discount to the average of the low 2 closing bid prices for the Company’s common stock for the five trading days immediately prior to such day that a holder delivers a notice of conversion to the Company, subject to adjustment.
|
Exhibit No.
|
Description
|
|
3.1
|
Series C Certificate of Designation, filed with the Secretary of State of the State of Nevada on October 25, 2011
|
MUSCLEPHARM CORPORATION
|
|||||
Date: November 4, 2011
|
By:
|
/s/ Brad J. Pyatt
|
|||
Name: Brad J. Pyatt
|
|||||
Title: Chief Executive Officer
|
1 Year Muscle Pharm (CE) Chart |
1 Month Muscle Pharm (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions